Clinical and bacteriological efficacy of rifampin-streptomycin combination for two weeks followed by rifampin and clarithromycin for six weeks for treatment of Mycobacterium ulcerans disease

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 2, 2014, Pages 1161-1166

  Phillips, Richard O ^a,b   Sarfo, Fred S ^a   Abass, Mohammed K ^d   Abotsi, Justice ^d   Wilson, Tuah ^f   Forson, Mark ^e   Amoako, Yaw A ^a   Thompson, William ^d   Asiedu, Kingsley ^g   Wansbrough Jones, Mark ^c  

^a KOMFO ANOKYE TEACHING HOSPITAL   (Ghana)

^b KWAME NKRUMAH UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Ghana)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^d Agogo Presbyterian Hospital   (Ghana)

^e Tepa Government Hospital   (Ghana)

^f Nkawie Toase Government Hospital   (Ghana)

^g WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CLARITHROMYCIN; RIFAMPICIN; STREPTOMYCIN;

ACID FAST BACTERIUM; ADOLESCENT; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM CULTURE; BURULI ULCER; CHILD; CLINICAL FEATURE; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM ULCERANS; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SKIN ULCER; SURVIVAL; TREATMENT RESPONSE; ULCER HEALING; VESTIBULOCOCHLEAR NERVE DISEASE; WOUND DRESSING;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; BURULI ULCER; CHILD; CHILD, PRESCHOOL; CLARITHROMYCIN; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; GHANA; HUMANS; MIDDLE AGED; MYCOBACTERIUM ULCERANS; RIFAMPIN; SKIN; STREPTOMYCIN; TREATMENT OUTCOME;

EID: 84893484637     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02165-13     Document Type: Article

References (37)

1. Revill WD, Morrow RH, Pike MC, Ateng J. 1973. A controlled trial of the treatment of Mycobacterium ulcerans infection with clofazimine. Lancet ii:873-877.
2. Amofah G, Asamoah S, Afram-Gyening C. 1998. Effectiveness of excision of pre-ulcerative Buruli lesions in field situations in a rural district in Ghana. Trop. Doct. 28:81-83.
3. Teelken MA, Stienstra Y, Ellen DE, Quarshie E, Klutse E, van der Graaf WT, van der Werf TS. 2003. Buruli ulcer: differences in treatment outcome between two centres in Ghana. Acta Trop. 88:51-56. http://dx.doi.org/10.1016/ S0001-706X(03)00170-0.
4. Debacker M, Aguiar J, Steunou C, Zinsou C, Meyers WM, Portaels F. 2005. Buruli ulcer recurrence, Benin. Emerg. Infect. Dis. 11:584-589. http://dx.doi.org/10.3201/eid1104.041000.
5. O'Brien DP, Hughes AJ, Cheng AC, Henry MJ, Callan P, McDonald A, Holten I, Birrell M, Sowerby JM, Johnson PD, Athan E. 2007. Outcomes for Mycobacterium ulcerans infection with combined surgery and antibiotic therapy: findings from a south-eastern Australian case series. Med. J. Aust. 186:58-61.
6. Havel A, Pattyn SR. 1975. Activity of rifampicin on Mycobacterium ulcerans. Ann. Soc. Belg. Med. Trop. 55:105-108.
7. Thangaraj HS, Adjei O, Allen BW, Portaels F, Evans MR, Banerjee DK, Wansbrough-Jones MH. 2000. In vitro activity of ciprofloxacin, sparfloxacin, ofloxacin, amikacin and rifampicin against Ghanaian isolates of Mycobacterium ulcerans. J. Antimicrob. Chemother. 45:231-233. http://dx.doi.org/10.1093/jac/ 45.2.231.
8. Portaels F, Traore H, De Ridder K, Meyers WM. 1998. In vitro susceptibility of Mycobacterium ulcerans to clarithromycin. Antimicrob. Agents Chemother. 42:2070-2073.
9. Stanford JL, Phillips I. 1972. Rifampicin in experimental Mycobacterium ulcerans infection. J. Med. Microbiol. 5:39-45. http://dx.doi.org/10.1099/ 00222615-5-1-39.
10. Bentoucha A, Robert J, Dega H, Lounis N, Jarlier V, Grosset J. 2001. Activities of new macrolides and fluoroquinolones against Mycobacterium ulcerans infection in mice. Antimicrob. Agents Chemother. 45:3109-3112. http://dx.doi.org/10.1128/AAC.45.11.3109-3112.2001.
11. Almeida D, Converse PJ, Ahmad Z, Dooley KE, Nuermberger EL, Grosset JH. 2011. Activities of rifampin, Rifapentine and clarithromycin alone and in combination against mycobacterium ulcerans disease in mice. PLoS Negl. Trop. Dis. 5:e933. http://dx.doi.org/10.1371/journal.pntd.0000933.
12. Ji B, Chauffour A, Robert J, Jarlier V. 2008. Bactericidal and sterilizing activities of several orally administered combined regimens against Mycobacterium ulcerans in mice. Antimicrob. Agents Chemother. 52:1912-1916. http://dx.doi.org/10.1128/AAC.00193-08.
13. Ji B, Chauffour A, Robert J, Lefrancois S, Jarlier V. 2007. Orally administered combined regimens for treatment of Mycobacterium ulcerans infection in mice. Antimicrob. Agents Chemother. 51:3737-3739. http://dx.doi.org/10.1128/ AAC.00730-07.
14. Etuaful S, Carbonnelle B, Grosset J, Lucas S, Horsfield C, Phillips R, Evans M, Ofori-Adjei D, Klustse E, Owusu-Boateng J, Amedofu GK, Awuah P, Ampadu E, Amofah G, Asiedu K, Wansbrough-Jones M. 2005. Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans. Antimicrob. Agents Chemother. 49:3182-3186. http://dx.doi.org/10.1128/AAC.49.8.3182-3186.2005.
15. World Health Organization. 2004. Provisional guidance on the role of specific antibiotics in the management of Buruli ulcer. World Health Organization, Geneva, Switzerland. http://www.who.int/buruli/information/ antibiotics/en.
16. Sarfo FS, Phillips R, Asiedu K, Ampadu E, Bobi N, Adentwe E, Lartey A, Tetteh I, Wansbrough-Jones M. 2010. Clinical efficacy of combination of rifampin and streptomycin for treatment of Mycobacterium ulcerans disease. Antimicrob. Agents Chemother. 54:3678-3685. http://dx.doi.org/10.1128/AAC.00299-10.
17. Nienhuis WA, Stienstra Y, Thompson WA, Awuah PC, Abass KM, Tuah W, Awua-Boateng NY, Ampadu EO, Siegmund V, Schouten JP, Adjei O, Bretzel G, van der Werf TS. 2010. Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial. Lancet 375:664-672. http://dx.doi.org/10.1016/S0140-6736(09)61962-0.
18. Phillips R, Horsfield C, Kuijper S, Lartey A, Tetteh I, Etuaful S, Nyamekye B, Awuah P, Nyarko KM, Osei-Sarpong F, Lucas S, Kolk AH, Wansbrough-Jones M. 2005. Sensitivity of PCR targeting the IS2404 insertion sequence of Mycobacterium ulcerans in an Assay using punch biopsy specimens for diagnosis of Buruli ulcer. J. Clin. Microbiol. 43:3650-3656. http://dx.doi.org/10.1128/JCM.43.8.3650-3656.2005.
19. Phillips RO, Sarfo FS, Osei-Sarpong F, Boateng A, Tetteh I, Lartey A, Adentwe E, Opare W, Asiedu KB, Wansbrough-Jones M. 2009. Sensitivity of PCR targeting Mycobacterium ulcerans by use of fine-needle aspirates for diagnosis of Buruli ulcer. J. Clin. Microbiol. 47:924-926. http://dx.doi.org/10.1128/JCM. 01842-08.
20. Palomino JC, Portaels F. 1998. Effects of decontamination methods and culture conditions on viability of Mycobacterium ulcerans in the BACTEC system. J. Clin. Microbiol. 36:402-408.
21. Dega H, Bentoucha A, Robert J, Jarlier V, Grosset J. 2002. Bactericidal activity of rifampin-amikacin against Mycobacterium ulcerans in mice. Antimicrob. Agents Chemother. 46:3193-3196. http://dx.doi.org/10.1128/AAC.46.10. 3193-3196.2002.
22. Alffenaar JW, Nienhuis WA, de Velde F, Zuur AT, Wessels AM, Almeida D, Grosset J, Adjei O, Uges DR, van der Werf TS. 2010. Pharmacokinetics of rifampin and clarithromycin in patients treated for Mycobacterium ulcerans infection. Antimicrob. Agents Chemother. 54: 3878-3883. http://dx.doi.org/10.1128/AAC. 00099-10.
23. Phillips R, Sarfo FS, Guenin-Mace L, Decalf J, Wansbrough-Jones M, Albert ML, Demangel C. 2009. Immunosuppressive signature of cutaneous Mycobacterium ulcerans infection in the peripheral blood of patients with Buruli ulcer disease. J. Infect. Dis. 200:1675-1684. http://dx.doi.org/10.1086/646615.
24. O'Brien DP, Robson M, Friedman ND, Walton A, McDonald A, Callan P, Hughes A, Rahdon R, Athan E. 2013. Incidence, clinical spectrum, diagnostic features, treatment and predictors of paradoxical reactions during antibiotic treatment of Mycobacterium ulcerans infections. BMC Infect. Dis. 13:416. http://dx.doi.org/10.1186/1471-2334-13-416.
25. O'Brien DP, Robson ME, Callan PP, McDonald AH. 2009. " Paradoxical" immune-mediated reactions to Mycobacterium ulcerans during antibiotic treatment: a result of treatment success, not failure. Med. J. Aust. 191:564-566.
26. Ruf MT, Chauty A, Adeye A, Ardant MF, Koussemou H, Johnson RC, Pluschke G. 2011. Secondary Buruli ulcer skin lesions emerging several months after completion of chemotherapy: paradoxical reaction or evidence for immune protection? PLoS Negl. Trop. Dis. 5:e1252. http://dx.doi.org/10.1371/journal. pntd.0001252.
27. Nienhuis WA, Stienstra Y, Abass KM, Tuah W, Thompson WA, Awuah PC, Awuah-Boateng NY, Adjei O, Bretzel G, Schouten JP, van der Werf TS. 2012. Paradoxical responses after start of antimicrobial treatment in Mycobacterium ulcerans infection. Clin. Infect. Dis. 54:519-526. http://dx.doi.org/10.1093/ cid/cir856.
28. Breen RA, Smith CJ, Bettinson H, Dart S, Bannister B, Johnson MA, Lipman MC. 2004. Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection. Thorax 59:704-707. http://dx.doi.org/10.1136/thx. 2003.019224.
29. Bloch S, Wickremasinghe M, Wright A, Rice A, Thompson M, Kon OM. 2009. Paradoxical reactions in non-HIV tuberculosis presenting as endobronchial obstruction. Eur. Respir. Rev. 18:295-299. http://dx.doi.org/10.1183/09059180. 00003709.
30. Wendel KA, Alwood KS, Gachuhi R, Chaisson RE, Bishai WR, Sterling TR. 2001. Paradoxical worsening of tuberculosis in HIV-infected persons. Chest 120:193-197. http://dx.doi.org/10.1378/chest.120.1.193.
31. Cheng VC, Ho PL, Lee RA, Chan KS, Chan KK, Woo PC, Lau SK, Yuen KY. 2002. Clinical spectrum of paradoxical deterioration during antituberculosis therapy in non-HIV-infected patients. Eur. J. Clin. Microbiol. Infect. Dis. 21:803-809. http://dx.doi.org/10.1007/s10096-002-0821-2.
32. Chauty A, Ardant MF, Adeye A, Euverte H, Guedenon A, Johnson C, Aubry J, Nuermberger E, Grosset J. 2007. Promising clinical efficacy of streptomycin-rifampin combination for treatment of Buruli ulcer (Mycobacterium ulcerans disease). Antimicrob. Agents Chemother. 51:4029-4035. http://dx.doi.org/10.1128/AAC.00175-07.
33. Kibadi K, Boelaert M, Kayinua M, Minuku JB, Muyembe-Tamfum JJ, Portaels F, Lefevre P. 2009. Therapeutic itineraries of patients with ulcerated forms of Mycobacterium ulcerans (Buruli ulcer) disease in a rural health zone in the Democratic Republic of Congo. Trop. Med. Int. Health 14:1110-1116. http://dx.doi.org/10.1111/j.1365-3156.2009.02324.x.
34. Gordon CL, Buntine JA, Hayman JA, Lavender CJ, Fyfe JA, Hosking P, Starr M, Johnson PD. 2010. All-oral antibiotic treatment for Buruli ulcer: a report of four patients. PLoS Negl. Trop. Dis. 4:e770. http://dx.doi.org/10.1371/journal. pntd.0000770.
35. Jenkin GA, Smith M, Fairley M, Johnson PD. 2002. Acute, oedematous Mycobacterium ulcerans infection in a farmer from far north Queensland. Med. J. Aust. 176:180-181.
36. Chauty A, Ardant MF, Marsollier L, Pluschke G, Landier J, Adeye A, Goundote A, Cottin J, Ladikpo T, Ruf T, Ji B. 2011. Oral treatment for Mycobacterium ulcerans infection: results from a pilot study in Benin. Clin. Infect. Dis. 52:94-96. http://dx.doi.org/10.1093/cid/ciq072.
37. Friedman ND, Athan E, Hughes AJ, Khajehnoori M, McDonald A, Callan P, Rahdon R, O'Brien DP. 2013. Mycobacterium ulcerans disease: experience with primary oral medical therapy in an Australian cohort. PLoS Negl. Trop. Dis. 7:e2315. http://dx.doi.org/10.1371/journal.pntd.0002315.